Han Ying - 14 Aug 2024 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Role
Chief Executive Officer, Director
Signature
/s/ Ruoyu Chen, as attorney-in-fact for Han Ying
Issuer symbol
GYRE
Transactions as of
14 Aug 2024
Net transactions value
$0
Form type
4
Filing time
16 Aug 2024, 20:50:24 UTC
Previous filing
01 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GYRE Stock Option (Right to Buy) Award $0 +341,000 $0.000000 341,000 14 Aug 2024 Common Stock 341,000 $9.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 341,000 shares of the Issuer's common stock, 25% of which will vest on August 14, 2025, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.